esperoct®

antihemophilic factor (recombinant), glycopegylated-exei

SAMPLE PROGRAM

Gain clinical experience with Esperoct®, an EHL flexibility factor¹.a

*Prior to reconstitution, Esperoct® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months. See Prescribing Information for complete product storage information.

INDICATIONS AND USAGE

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes

 Esperoct[®] is not indicated for the treatment of von Willebrand disease

FHI = extended half-life



Please see Important Safety Information throughout.

Please see Prescribing Information here.



Model is for illustrative purposes only.


Esperoct[®]:

THE FLEXIBILITY FACTOR

FOR WHEREVER THEIR DAY TAKES THEM^{1,a}

Esperoct®—an EHL flexibility factor that offers¹-6:









Novo Nordisk is pleased to provide Esperoct® samples to eligible practitioners for appropriate patients.

You will receive 18,000 IUs of Esperoct® in the following vial sizes as a single shipment^d:

Product #	7101958		7101954		7101955	
Vial Size	500 IU	\$500 IU are	1000 IU	©0169 8101 111 ESPEROCT®	3000 IU	\$\$PEROCT 8 8300 IUM
Qty.	6	Reconfliction with a precipitation of the precipita	6	sconophilic with many and a continuous with many and a proper and a continuous and a c	3	tomorphile system of the control of

^aPrior to reconstitution, Esperoct[®] can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months.¹ See Prescribing Information for complete product storage information.

IMPORTANT SAFETY INFORMATION

Contraindications

 Do not use in patients who have known hypersensitivity to Esperoct[®] or its components, including hamster proteins

Please see Important Safety Information throughout. Please see Prescribing Information <u>here.</u>



antihemophilic factor (recombinant), glycopegylated-exei

^bBased on bleeding episodes. See Prescribing Information for complete dosing instructions.

^cSome restrictions apply to participation.

^dA valid state license number is required to order samples.

esperoct®

antihemophilic factor (recombinant), glycopegylated-exei

To enroll in the Esperoct® Sample Program, please contact your Novo Nordisk representative

Scan this code using the camera on your smartphone to find a local representative.



IMPORTANT SAFETY INFORMATION (cont'd) Warnings and Precautions

- Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
- Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
- Temporary decrease in Factor VIII incremental recovery (IR) has been observed after Esperoct® infusion, within the first 5 exposure days, in previously untreated patients (PUPs) <6 years of age. During the decreased IR period, these subjects may have an increased bleeding tendency. If bleeding is not controlled with the recommended dose of Esperoct® and/or the expected Factor VIII activity levels are not attained and Factor VIII inhibitors are not detected, consider adjusting the dose, dosing frequency, or discontinuing Esperoct®

Adverse Reactions

• The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions. Additional frequently reported adverse reactions (≥1%) in PUPs included Factor VIII inhibition and hypersensitivity.

REFERENCES: 1. Esperoct® [package insert]. Plainsboro, NJ: Novo Nordisk Inc. 2. Eloctate® [package insert]. Bioverativ Therapeutics Inc; 2023. 3. Adynovate® [package insert]. Lexington, MA: Baxalta US Inc.; 2023. 4. Jivi® [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2018. 5. Altuviiio® [package insert]. Bioverativ Therapeutics Inc; 2023. 6. Afstyla® [package insert]. Marburg, Germany: CSL Behring GmbH; 2023.



Please see Important Safety Information throughout. Please see Prescribing Information <u>here.</u>

Novo Nordisk Inc., 800 Scudders Mill Road, Plainsboro, New Jersey 08536 U.S.A. Esperoct® is a registered trademark of Novo Nordisk Health Care AG. Novo Nordisk is a registered trademark of Novo Nordisk A/S.

© 2024 Novo Nordisk All rights reserved. US24ESP00020 April 2024